ARTICLES BY LORI CLAPPER

• Celgene Wins Rights To Moffitt’s Investigational MDS Therapy

  11/20/2014

  The Moffitt Cancer Center announced Monday that it has entered an exclusive licensing agreement with Celgene Corporation, which gives Celgene the exclusive rights to its novel, investigational therapy for Myelodysplastic Syndromes (MDS).

• Biogen Idec Shells Out $10 M Milestone To Isis For New Investigational Drug R&D

  11/14/2014

  Biogen Idec paid Isis Pharmaceuticals a $10 million milestone payment after the launch of studies to support an Investigation New Drug application (IND) for its neurodegenerative disease treatment, ISIS-BIIB3 _Rx.

• Celgene Announces Positive Data For Crohn’s Disease Drug

  10/24/2014

  Celgene announced positive results Monday of its double blind multicenter Phase 2 trial of its Crohn’s Disease drug, GED-0301. The company presented the data from the study, Mongersen, an Oral smad7 Antisense Oligonucleotide, in Active Crohn's Disease Tuesday at the United European Gastroenterology Week in Vienna, Austria.

• New Initiative Launched To Promote Biotech Education

  10/22/2014

  The Biogen Idec Foundation is offering up a $1.5 million grant in an effort to boost the biotechnology industry’s visibility.

• Actavis Adds To Infectious Disease Portfolio With Durata Merger

  10/8/2014

  Actavis and Durata Therapeutics announced a $675 million merger agreement Tuesday, in which an Actavis subsidiary will acquire all of the outstanding shares of Durata.

• Servier Enters R&D Partnership To Find Effective Blood Cancer Treatments

  10/7/2014

  French pharmaceutical company Servier and the Walter and Eliza Hall Institute, Australia’s oldest medical research organization, have entered into a partnership to develop new agents specifically targeted to treat blood cancers, as well as other types of the disease.

• Tropical Disease Treatment At Heart Of New Research Collaboration

  9/26/2014

  Celgene Global Health (CGH), a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative (DNDi) inked a four-year research collaboration agreement Wednesday. The organizations will expand on the parties’ ongoing collaboration in order to discover and produce new treatment options for neglected tropical diseases (NTDs).

• Sobi, Biogen Idec Expand Hemophilia Portfolio

  9/24/2014

  Swedish company Sobi announced it will be adding its preclinical hemophilia A candidate to the company's existing collaboration with Biogen Idec.

• U.S. Government Takes Steps To Combat Antibiotic Resistance

  9/23/2014

  The U.S. government initiated a new strategy last week to track trends in antibiotic resistance, due to reports that it is the cause for at least 23,000 deaths and two million illnesses each year.  The plan lays out specific steps to prevent this epidemic and to accelerate the research and development of new antibiotics by 2020.

• Mylan, Gilead Partner To Bring Cheaper Hepatitis C Treatment To Developing Countries

  9/18/2014

  In a new collaboration with Gilead Sciences, Mylan has won the nonexclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Gilead currently markets Sovaldi, the brand-name version of sofosbuvir, indicated for those with hepatitis C.

• Biogen Idec Announces Strides In Clinical Studies For MS Treatments

  9/18/2014

  Biogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston last week.

• More Vaccines Needed For Tropical Diseases, Study Reveals

  9/17/2014

  There has been quite a clamor recently about the record-setting outbreak of the deadly Ebola virus in West Africa, which has killed over 2,200 people to date and spurred numerous strategies in an effort to control it, including a new vaccine and other experimental drugs.

• Celgene’s Combination Regimen For Multiple Myeloma Reaches Primary Endpoint

  9/8/2014

  Celgene announced that its findings from its open-label phase III randomized study of Revlimid (lenalidomide) in combination with dexamethasone had met its primary endpoint of progression free survival (PFS).  The research was performed in newly diagnosed multiple myeloma (NDMM) patients who are not candidates for stem cell transplants.

• FDA Approves NDA For Actavis’ Investigational IBS Treatment

  9/5/2014

  The U.S. Food and Drug Administration (FDA) has accepted Actavis' New Drug Application (NDA) filing for its investigational treatment of symptoms like diarrhea and abdominal pain associated with Irritable Bowel Syndrome. Eluxadoline was also granted priority review by the FDA, the company said in an announcement.

• New Animal Resource Facility India’s Latest R&D Move

  9/2/2014

  India’s department of health research announced that the country plans to build its first ever National Animal Resource facility for biomedical research that will only accept animals of a “defined quality.” This will empower researchers to obtain more reliable results for vaccine development.